Prothena PRTA Stock
Prothena Price Chart
Prothena PRTA Financial and Trading Overview
| Prothena stock price | 10.75 USD |
| Previous Close | 6.47 USD |
| Open | 6.54 USD |
| Bid | 6.23 USD x 100 |
| Ask | 6.32 USD x 100 |
| Day's Range | 6.25 - 6.62 USD |
| 52 Week Range | 4.32 - 25.42 USD |
| Volume | 788.84K USD |
| Avg. Volume | 1.81M USD |
| Market Cap | 336.96M USD |
| Beta (5Y Monthly) | -0.079 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.62 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.29 USD |
PRTA Valuation Measures
| Enterprise Value | -81002216 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.4558139 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.442868 |
| Price/Book (mrq) | 0.76989305 |
| Enterprise Value/Revenue | -0.587 |
| Enterprise Value/EBITDA | 0.588 |
Trading Information
Prothena Stock Price History
| Beta (5Y Monthly) | -0.079 |
| 52-Week Change | -74.32% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 25.42 USD |
| 52 Week Low | 4.32 USD |
| 50-Day Moving Average | 6.08 USD |
| 200-Day Moving Average | 12.12 USD |
PRTA Share Statistics
| Avg. Volume (3 month) | 1.81M USD |
| Avg. Daily Volume (10-Days) | 772.15K USD |
| Shares Outstanding | 53.83M |
| Float | 40.66M |
| Short Ratio | 2.24 |
| % Held by Insiders | 18.98% |
| % Held by Institutions | 73.94% |
| Shares Short | 4.66M |
| Short % of Float | 16.26% |
| Short % of Shares Outstanding | 8.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | -79.94% |
| Operating Margin (ttm) | -2318.98% |
| Gross Margin | -51.67% |
| EBITDA Margin | -99.83% |
Management Effectiveness
| Return on Assets (ttm) | -15.49% |
| Return on Equity (ttm) | -23.45% |
Income Statement
| Revenue (ttm) | 137.94M USD |
| Revenue Per Share (ttm) | 2.56 USD |
| Quarterly Revenue Growth (yoy) | 5556.00% |
| Gross Profit (ttm) | -71281000 USD |
| EBITDA | -137712992 USD |
| Net Income Avi to Common (ttm) | -110266000 USD |
| Diluted EPS (ttm) | -2.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 417.94M USD |
| Total Cash Per Share (mrq) | 7.76 USD |
| Total Debt (mrq) | 10.2M USD |
| Total Debt/Equity (mrq) | 2.33 USD |
| Current Ratio (mrq) | 9.001 |
| Book Value Per Share (mrq) | 8.131 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -130362000 USD |
| Levered Free Cash Flow (ttm) | -35384752 USD |
Profile of Prothena
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | 77 Sir John Rogerson’s Quay |
| ZIP | D02 VK60 |
| Phone | 353 1 236 2500 |
| Website | https://www.prothena.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 163 |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Q&A For Prothena Stock
What is a current PRTA stock price?
Prothena PRTA stock price today per share is 10.75 USD.
How to purchase Prothena stock?
You can buy PRTA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prothena?
The stock symbol or ticker of Prothena is PRTA.
Which industry does the Prothena company belong to?
The Prothena industry is Biotechnology.
How many shares does Prothena have in circulation?
The max supply of Prothena shares is 53.83M.
What is Prothena Price to Earnings Ratio (PE Ratio)?
Prothena PE Ratio is now.
What was Prothena earnings per share over the trailing 12 months (TTM)?
Prothena EPS is -5.62 USD over the trailing 12 months.
Which sector does the Prothena company belong to?
The Prothena sector is Healthcare.
Prothena PRTA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
| US Tech Biotechnology Total Retu XNBI | 5830.62 USD — |
+1.2
|
— — | 5732.51 USD — | 5837.42 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2566.34 USD — |
+0.47
|
— — | 2546.3 USD — | 2571.79 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 11620.1 USD — |
+0.59
|
— — | 11575.56 USD — | 11733.88 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 29137.78 USD — |
+0.62
|
— — | 29019.72 USD — | 29409.52 USD — | — - | — — |
| US Tech US Smart Pharmaceuticals NQSSPH | 1603.8 USD — |
+0.75
|
— — | 1582.27 USD — | 1607.03 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 3514.71 USD — |
+0.87
|
— — | 3485.13 USD — | 3527.41 USD — | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
- {{ link.label }} {{link}}